Stage
No active trials
Next date
None yet
Trials
46 active
58 in total · 57 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “IOA-289 will be administered orally twice daily (BID), starting from C0D1. Gemcitabine and nab-paclitaxel will be administrated by IV infusion, weekly for 3 weeks of a 4 week cycle starting at C1D1.”In the company’s words, NCT05586516 on ClinicalTrials.gov
- Tested for
- Metastatic Pancreatic Cancer
- Main trialPhase 1/2
- “The objective of study IOA-289-102 is to evaluate the safety and tolerability of escalating doses of IOA-289 in patients with metastatic pancreatic cancer in combination with standard chemotherapy consisting of gemcitabine and nab-paclitaxel. Blood and tumour samples for PK and PD will be collected and assessments for determination of any clinical efficacy will be completed.”In the company’s words, NCT05586516 on ClinicalTrials.gov
- Other names
- gemcitabine · nab-paclitaxel · Abraxane
Other drugs for Metastatic Pancreatic Cancer
- CAM2029Camurus AB · Phase 3
- Immuncell-LCGC Cell Corporation · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- XNW28012Evopoint Biosciences Inc. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- DaraxonrasibRevolution Medicines · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials58
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Completed | 18 Aug 2025 | A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer | |
| Phase 1Completed | 7 Sep 2021 | A Study to Assess an ATX Inhibitor (IOA-289) in Healthy Volunteers | |
| Phase 2Authorised | not given | Preoperative treatment with mFOLFIRINOX (or Gem-Nab-P) +/- isotoxic high-dose Stereotactic Body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma: a randomised comparative multicentre phase II study (STEREOPAC) | |
| Phase 3Authorised | not given | Standard versus Prolonged Neoadjuvant (Conversion) Chemotherapy to prolong survival of patients with Borderline and Locally Advanced Pancreatic Cancer: a phase III randomized controlled trial | |
| Phase 2Authorised | not given | HOVON 164 HL: Tislelizumab plus Gemcitabine and Cisplatin for Relapsed or Refractory Hodgkin Lymphoma followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (TIGERR-HL). An open label phase II trial. | |
| Phase 4Authorised | not given | LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES | |
| Phase 2/3Authorised | not given | A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY Study. | |
| Phase 3Authorised | not given | Adjuvant instillations in intermediate risk NMIBC: A Study comparIng Gemcitabine and MitomYciN (SIGYN-trial) | |
| Phase 2Authorised | not given | TRAP-BTC Efficacy and safety of GemCis plus Trastuzumab plus Pembrolizumab in previously untreated HER2-positive biliary tract cancer | |
| Phase 2Authorised | not given | The CLEAN-DUCT / TRITICC-3 trial - Phase IIa, prospective, single arm, open label, non-randomized, multi-center pilot study of durvalumab (MEDI4736) + intraductal radiofrequency ablation (ID-RFA) in extra- and intrahepatic cholangiocarcinoma | |
| Phase 3Authorised | not given | TIming of start of systemIc treatment for asymptomatic MEtastasized PANcreatic cancer (TIMEPAN): a prospective multicenter patient preference cohort | |
| Phase 2Ended | not given | TARSARC : TARGETING ATR IN SOFT-TISSUE SARCOMAS: A RANDOMIZED PHASE II STUDY | |
| Phase 4Authorised | not given | zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric randomized clinical study with intervention | |
| Phase 2Authorised | not given | An open-label single arm interventional phase 2 study to investigate outcome of individualized treatment based on pharmacogenomic profiling and ex vivo drug sensitivity testing of patient-derived organoids in patients with metastatic colorectal cancer | |
| Phase 1Authorised | not given | Individualized Systems Medicine strategy to target cancer stem cells in patients with recurrent Glioblastoma (ISM-GBM) | |
| Phase 2Authorised | not given | Using organoids to predict efficacy of adjuvant treatment to improve outcome in resectable pancreatic cancer (UNITEPANC) | |
| Phase 1/2Authorised | not given | A phase I/II b (randomized controlled) study of atezolizumab combined to BEGEV regimen as first salvage treatment in patients with relapsed or refractory Hodgkin’s lymphoma candidate to autologous stem–cell transplantation | |
| Phase 2Authorised | not given | The role of sonoporation-enhanced treatment with Gemcitabine, Nab-Paclitaxel and FOLFIRINOX in patients with inoperable pancreatic cancer | |
| Phase 4Authorised | not given | RANDOMIZED CLINICAL TRIAL, OPEN, TO EVALUATE THE BLADDER INSTILLATION OF NEOADYUVANT CHEMOTHERAPY TO THE TRANSURETHAL RESECTION OF BLADDER FOR THE PREVENTION OF RECURRENCE OF NONMUSCLE-INVASIVE UROTHELIAL CARCINOMA | |
| Phase 1/2Authorised | not given | A Phase 1b/2, Safety Lead-in and Dose-Expansion, Open label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination with Durvalumab and Gemcitabine/Cisplatin as First-line Therapy in Participants with Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation | |
| Phase 2Authorised | not given | A randomized phase II study of gemcitabine versus reduced-dose combination chemotherapy in fragile patients with non-resectable pancreatic cancer | |
| Phase 3Authorised | not given | A clinical trial in children and adolescents with primary malignant liver cancer - Hepatoblastoma and Hepatocarcinoma | |
| Phase 3Authorised | not given | An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature (ESPAC-6) | |
| Phase 1/2Not authorised | not given | Phase I/II randomized clinical trial of selinexor plus gemcitabine in selected advanced soft-tissue sarcomas | |
| Phase 2/3Halted | not given | ALICE : An integrated Phase II/III randomized study comparing durvalumab and tremelimumab +/- Hepatic ArteriaL Infusion Chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn | |
| Phase 2Authorised | not given | Neo-adjuvant versus Adjuvant chemotherapy in Upper Tract Urothelial Carcinoma: A feasibility phase II randomized clinical trial (“URANUS”) | |
| Phase 3Authorised | not given | Gemcitabine plus nab-PAclitaxel as switch maiNTEnance versus cONtinuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: the PANThEON phase III Trial. | |
| Phase 2Authorised | not given | PHASE II study evaluating the benefit of Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer | |
| Phase 2Ended | not given | Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (NeoTreme) | |
| Phase 2Authorised | not given | Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable, high-risk, localized urothelial carcinoma of the upper urinary tract. iNDUCT - GETUG V08 | |
| Phase 2/3Authorised | not given | rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma | |
| Phase 3Authorised | not given | PHITT: Paediatric Hepatic International Tumour Trial | |
| Phase 4Authorised | not given | PROSPECTIVE EVALUATION OF THE DDR GENES ALTERATION TO PREDICT RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED UROTHELIAL CANCER | |
| Phase 2Authorised | not given | Precision Medicine in patients with unresectable CholAngiocarcinoma; RadioEmbolization and combined biological therapy (PM-CARE). Single arm, multicenter phase II study investigating the efficacy and safety of a novel therapeutic scheme in patients with unresectable CholAngiocarcinoma; RadioEmbolization in combination with CisGem and Durvalumab (MEDI4736) | |
| Phase 2/3Authorised | not given | Neoadjuvant gemcitabine and cisplatin in combination with perioperative pembrolizumab versus upfront surgery for patients with primary resectable and borderline resectable perihilar and distal cholangiocarcinoma (NEODISCO): A Multicentre Phase 2B/3 Randomised Controlled Trial | |
| Phase 2Authorised | not given | COBRA - Chemoablation for Low Grade Bladder Cancer: A single arm, prospective, open-label, investigator-initiated Phase 2 study | |
| Phase 3Ended | not given | Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) | |
| Phase 2Authorised | not given | Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer : a multicentre, randomised, phase 2 trial (Nordic Pancreatic Cancer Trial (NORPACT) – 1 | |
| Phase 2/3Authorised | not given | PRODIGE 61- FFCD 1702 - FUNGEMAX Randomized phase II study comparing 5FU/LV+Nal-IRI, gemcitabine+Nab-paclitaxel or a sequential regimen of 2 months 5FU/LV+Nal-IRI followed by two months of gemcitabine+Nab-paclitaxel, in metastatic pancreatic cancer | |
| Phase 1/2Ended | not given | LAPTOP: PHASE 1/2 STUDY IN BORDELINE RESECTABLE, LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER TO ASSESS SAFETY AND POTENTIAL EFFICACY OF DUAL CHECKPOINT INHIBITION IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL FOLLOWED BY IMMUNE-CHEMORADIATION. | |
| Phase 2Authorised | not given | A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/HGBCL relapse | |
| Phase 3Not authorised | not given | Evaluation of the efficacy and safety of the combination of platinum-based chemotherapy (Gemcitabin/Cisplatin) and immunotherapy compared with platinum-based chemotherapy alone in neoadjuvant setting before surgery of high-grade localized upper tract urothelial carcinoma (UTUC). | |
| Phase 2Ended | not given | Neo-adjuvant Chemo and immunotherapy with durvalumab (MEDI4736) and tremelimumab (MEDI1123) In The pre-operAtive Treatment of locally advanced cholangIOcarciNoma: an exploratory and translational study. | |
| Phase 2Authorised | not given | Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy with systemic Nabpaclitaxel-Gemcitabine chemotherapy for pancreatic cancer peritoneal metastases. A single-arm, open-label, phase II trial. Nab-PIPAC Trial | |
| Phase 3Authorised | not given | A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC) | |
| Phase 2/3Authorised | not given | Risk-adapted adjuvant chemotherapy guided by the tumour stage for operated pancreatic adenocarcinoma following neoadjuvant chemotherapy with FOLFIRINOX FRENCH26 – PRODIGE93 - PANACHE02 Trial | |
| Phase 2Ended | not given | GEMOXIA02: HEPATIC ARTERIAL INFUSION OF GEMCITABINE-OXALIPLATIN FOR SECOND-LINE THERAPY IN NON-METASTATIC UNRESECTABLE INTRA-HEPATIC CHOLANGIOCARCINOMA: A MULTICENTRIC SINGLE-ARM PHASE II STUDY | |
| Phase 2/3Ended | not given | ORACLE - Randomized Phase 3 Study evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) compared to Investigator’s Choice Therapy in Patient with Relapsed or Refractory Angioimmunoblastic T cell Lymphoma | |
| Phase 2Authorised | not given | PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma. | |
| Phase 2Authorised | not given | TACTIC : MP0317, A TUMOR TARGETING FAP DEPENDENT CD40 AGONIST DARPIN, IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN FIRST LINE TREATMENT FOR PATIENTS WITH ADVANCED BILIARY TRACT CARCINOMA A RANDOMIZED NON COMPARATIVE PROOF OF CONCEPT PHASE II STUDY | |
| Phase 1/2Authorised | not given | Phase I/II randomized clinical trial of selinexor plus gemcitabine in selected advanced soft-tissue sarcomas | |
| Phase 2/3Authorised | not given | PRODIGE 118 - PEHRICCA : PErioperative CISGEM plus RILVEGOSTOMIG in High-Risk resectable Intrahepatic CholangioCarcinoma Phase II single arm study -mutlicenter | |
| Phase 3Authorised | not given | Toripalimab plus chemotherapy as first-line treatment for recurrent and/or metastatic nasopharyngeal cancer: safety and activity in non-endemic population | |
| Phase 2Authorised | not given | IFCT-2502 LIMPID Phase II trial assessing 1st line and 2nd line treatment in patients with advanced Non-Small Cell Lung Cancer and Interstitial Lung Disease | |
| Phase 1/2Authorised | not given | A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies | |
| Phase 2/3Authorised | not given | DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations” | |
| Phase 2Authorised | not given | SAKK 18/25: Overcoming Resistance to Immunotherapy combining Gemcitabine with Ivonescimab in advanced NSCLC progressing on immune checkpoint inhibitors: A multicenter, single-arm, open-label phase II trial (ORIGIN2) | |
| Phase 2Authorised | not given | COLOVERT – Conversion therapy in colorectal cancer with peritoneal metastases not amenable to upfront cytoreductive surgery and HIPEC: a phase II “pick-the-winner” open-label randomized trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026